Pyrazolylaminobenzimidazole derivatives as JAK inhibitors
申请人:Eli Lilly and Company
公开号:US10323019B2
公开(公告)日:2019-06-18
The present invention provides compounds of the formula below (I′): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.